retevmo
Retevmo (Selpercatinib) is a kinase inhibitor used to treat Non-Small-Cell Lung Carcinoma, Thyroid Neoplasms.
Selpercatinib · by Eli Lilly and Co
Key facts
- Active ingredient
- Selpercatinib
- Drug class
- Kinase Inhibitor
- Form
- Capsule, Tablet
- Strength
- Selpercatinib 40MG · Selpercatinib 80MG
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- Manufacturer
- Eli Lilly and Co
- FDA application
- NDA213246
Storing Retevmo, and how long it keeps
Quoted from this product’s own FDA label. Storage belongs to the product and its device, not to the drug in general — a pen and a tablet of the same medicine are kept completely differently.
- “Discard RETEVMO dispersion if not taken within 2 hours.”
Drug class
How this class works, per Tyrosine Kinase Inhibitors - StatPearls - NCBI Bookshelf.
May treat (source: NIH RxClass)
See how Retevmo ranks — best-rated kinase inhibitor for:
Dosage forms
Capsule and Tablet
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Retevmo treat?
- Retevmo (Selpercatinib) may be used to treat non-small-cell lung carcinoma, thyroid neoplasms, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How does Retevmo work?
- Retevmo is a kinase inhibitor. Kinase inhibitors block protein kinases, the enzymes that relay 'grow and divide' signals inside cells. By shutting down the overactive kinase signals that a tumor depends on, they help slow or stop cancer cells from multiplying.
- Is there a coupon or discount for Retevmo?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Retevmo. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Retevmo?
- Retevmo is marketed by Eli Lilly and Co. You can see Eli Lilly and Co's full profile, rating, and other products on pharmaranks.
- Is Retevmo a brand-name or generic drug?
- Retevmo is a brand-name product with the active ingredient Selpercatinib.
- Is Retevmo available over the counter?
- No. Retevmo is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Retevmo come in?
- Retevmo is currently marketed as capsule and tablet, per the FDA's National Drug Code Directory.
- What class of drug is Retevmo?
- Retevmo is classified as kinase inhibitor, per the FDA's Established Pharmacologic Class.
- Is Retevmo FDA-registered?
- Retevmo is on record with the U.S. FDA under application number NDA213246. You can verify this on its official FDA label.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about SELPERCATINIB
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 357 reports naming SELPERCATINIB — the active ingredient in Retevmo, and the FDA flagged 96% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- malignant neoplasm progression61 reports
- diarrhoea32 reports
- blood creatinine increased24 reports
- hypertension24 reports
- fatigue23 reports
- thrombocytopenia20 reports
- alanine aminotransferase increased19 reports
- aspartate aminotransferase increased19 reports
Read these as a signal, not a rate. A report does not mean SELPERCATINIB caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 26, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
danziten
Nilotinib Tartrate
everolimus
Everolimus
ofev
Nintedanib Esylate
sprycel
Dasatinib
afinitor
Everolimus
calquence
Acalabrutinib
Compare Retevmo head-to-head
More kinase inhibitor drugs
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
retevmo
New